Cancer gene and oncolytic virus therapy.

Area of Science:

• Oncology
• Gene Therapy
• Immunotherapy
• Virology

Background:

• Cancer represents the vast majority of global gene therapy trials.
• Seventy percent of gene therapy protocols reviewed by the NIH Recombinant DNA Advisory Committee (RAC) target cancer.
• A significant portion of these cancer gene therapy trials involve immunotherapy.

Purpose of the Study:

• To review current gene therapy strategies for cancer treatment.
• To explore the mechanisms of action for various gene and viral therapies.
• To highlight the potential and challenges of novel cancer therapies.

Main Methods:

• Analysis of gene therapy protocols submitted to the NIH RAC.
• Review of clinical studies involving immunotherapy, gene transfer, and oncolytic viruses.
• Examination of viral replication mechanisms and tumor selectivity strategies.

Main Results:

• Gene therapy for cancer primarily employs immunotherapy via gene transfer (cytokines, immune molecules, tumor antigens).
• Other strategies include chemoprotection, prodrug activation, and tumor-suppressor gene replacement.
• Replicating oncolytic viruses (e.g., herpes virus, reovirus) demonstrate selective cancer cell replication, with mechanisms like Ras pathway dependence or tumor-specific promoters.

Conclusions:

• Gene and viral therapies offer promising avenues for cancer treatment, with local or bystander effects contributing to antitumor activity.
• Oncolytic viruses can be engineered for enhanced tumor selectivity and immunogenicity.
• Further research is crucial to fully realize the potential of these novel therapeutic approaches in clinical settings.